+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statins and C-reactive protein levels

Statins and C-reactive protein levels

Journal of Clinical Hypertension 9(8): 622-628

In patients with or at risk for cardiovascular disease (CVD), including hypertensive individuals, lowering levels of low-density lipoprotein cholesterol (LDL-C) reduces CVD risk. Statins are the most effective of available therapies for lowering LDL-C. Extensive clinical trial data have shown that the degree of LDL-C reduction obtained depends on the particular statin used and that intensive LDL-C lowering reduces the incidence of cardiovascular events compared with more moderate LDL-C lowering. More recent data suggest that effects independent of LDL-C lowering may also play a part in the reduction in cardiovascular events. C-reactive protein (CRP), a marker of inflammation, is a potential predictor of CVD risk, and statins reduce CRP levels by up to 60%. CRP reduction is independent of LDL-C lowering, and variation between statins in CRP reduction may play some role in CVD event reduction rates. At present, however, there are few outcome data relating to the cardiovascular benefits of reducing CRP.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911654

Download citation: RISBibTeXText

PMID: 17673884

DOI: 10.1111/j.1524-6175.2007.06639.x

Related references

More evidence support benefits of statins for low-risk patients. Study adds more fuel to the debate on whether to prescribe statins for patients with low levels of C-reactive protein and LDL cholesterol. Dukemedicine Healthnews 17(5): 6-6, 2011

High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. Aids 25(16): 2053-2053, 2011

Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169(1): 155-158, July, 2003

Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia. Lipids in Health and Disease 14(): 107-107, 2016

Difference of high-sensitive C-reactive protein levels in patients treated with statins, aspirin, and angiotensin II modulators. Journal of the American College of Cardiology 39(5 Supplement A): 270A, March 6, 2002

Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arteriosclerosis, Thrombosis, and Vascular Biology 25(6): 1231-1236, 2005

In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease. European Journal of Vascular and Endovascular Surgery 37(4): 443-447, 2009

Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin. Heart and Vessels 30(6): 762-770, 2016

Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart 92(4): 495-498, 2005

Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease. Heart Asia 3(1): 130-134, 2011

Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein). Seminars in Vascular Surgery 24(3): 172-179, 2012

Increased expression of C-reactive protein and tissue factor in acute coronary syndrome lesions: Correlation with serum C-reactive protein, angioscopic findings, and modification by statins. Atherosclerosis 202(1): 135-143, 2008

Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. American Journal of Cardiology 93(6): 783-785, 2004

hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation. Heart Disease 5(1): 2-7, 2003